Quanterix Corporation Intrinsic Value – QUANTERIX CORPORATION Reports Q2 Earnings for FY2023 on August 7

August 14, 2023

🌥️Earnings Overview

On August 7 2023, QUANTERIX CORPORATION ($NASDAQ:QTRX) reported their earnings for the second quarter of FY2023, which ended on June 30 2023. They achieved total revenue of USD 30.9 million, representing a 31.8% increase from the same quarter last year. Furthermore, net income was USD -6.1 million, an improvement from -24.9 million in the prior year.

Share Price

QUANTERIX CORPORATION, a leader in the development of high definition diagnostics, reported its financial results for the second quarter of the fiscal year ending June 30, 2023. On Monday, August 7, QUANTERIX CORPORATION stock opened at 22.9 and closed at 21.7—a decrease of 5.0% from the previous closing price of 22.9. Despite a challenging business environment due to the global pandemic, QUANTERIX CORPORATION has continued to make progress and investments to advance its high definition diagnostics platform for new applications in biomedicine and clinical research.

The company also announced new collaborations with leading institutions to expand its reach and demonstrate the potential of its technology. As a result, the company remains optimistic about the future and confident that its position as a leader in precision diagnostics will help it continue to deliver long-term value for shareholders. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Quanterix Corporation. More…

    Total Revenues Net Income Net Margin
    111.08 -65.81 -43.4%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Quanterix Corporation. More…

    Operations Investing Financing
    -36.08 -11.21 2.31
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Quanterix Corporation. More…

    Total Assets Total Liabilities Book Value Per Share
    429.21 73.85 9.55
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Quanterix Corporation are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    23.0% -43.4%
    FCF Margin ROE ROA
    -41.9% -8.4% -7.0%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis – Quanterix Corporation Intrinsic Value

    Our team at GoodWhale has done an analysis of the fundamentals of QUANTERIX CORPORATION. After taking into account everything from their financials to their competitive positioning in the market, we have estimated that the intrinsic value of their share is around $35.7. We have determined this value through our proprietary Valuation Line. This implies that the stock is undervalued and presents a potential opportunity for investors. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    Its main competitors are Taiwan Advanced Nanotech Inc, Lucira Health Inc, and FluroTech Ltd. All of these companies are based in Taiwan and offer similar products and services.

    – Taiwan Advanced Nanotech Inc ($TPEX:6797)

    As of 2022, Taiwan Advanced Nanotech Inc has a market cap of 1.89B and a Return on Equity of 33.23%. The company is a leading provider of nanotechnology solutions and services. Its products and services are used in a wide range of applications, including semiconductor manufacturing, solar energy, LED lighting, and biomedical. The company has a strong market presence in Taiwan and China, and is expanding its operations globally.

    – Lucira Health Inc ($NASDAQ:LHDX)

    Lucira Health Inc is a medical technology company that develops and commercializes molecular diagnostics products. The company has a market cap of 16.04M and a ROE of -13.64%. Lucira Health’s products are designed to provide sensitive and specific molecular information to aid in the diagnosis, treatment and management of infectious diseases. The company’s products are based on its proprietary Lucira Molecular Detection Platform, which is a real-time PCR technology. Lucira Health’s products are CE-marked and are commercially available in Europe and the United States.

    – FluroTech Ltd ($TSXV:TEST)

    FluroTech Ltd is a Canadian company that provides technology solutions for the cannabis industry. Its products include a cannabis trichome analyzer, a cannabis oil and wax analyzer, and a cannabis potency tester. The company also offers consulting services for the cannabis industry.


    Quanterix Corporation reported impressive revenue growth in their second quarter financial results, with total revenue of USD 30.9 million, representing an increase of 31.8%, and net income of -6.1 million, improving from -24.9 million in the prior year. Despite this positive result, the stock price moved down the same day. Investors may be concerned about the continued net losses and should analyze the company’s performance and future prospects before making any investments. They should also take into consideration factors such as the competitive landscape and potential risks that could impact performance in future quarters.

    Recent Posts

    Leave a Comment